MIAMI & MEMPHIS, Tenn.--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) and Immuno Technologies, Inc. today announced that the National Institutes of Health (NIH) has awarded a $3 million grant to develop a rapid diagnostic test for Lyme disease. The Phase II Small Business Innovation Research (SBIR) grant was issued to Immuno Technologies working in collaboration with OPKO Diagnostics, LLC and Columbia University in the City of New York. The goal of the grant is to develop a rapid diagnostic test based upon novel antigens that increase the specificity and sensitivity of the current laboratory assays and improve discrimination between early and late stage disease using OPKO’s Claros®1 in office analyzer. Combinations of these antigens have already been successfully demonstrated on OPKO’s microfluidic cassettes for the detection of Lyme disease using challenge panels from patients.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.